NNO2

Novo Nordisk A/S Class B · VIE:NNO2

36.21 EUR0.5500 +1.54%

Novo Nordisk A/S Class B (VIE:NNO2) last traded at 36.21 EUR, up 1.54% on the day. Over the past year the stock is down 17.25%. Its 52-week range is 30.00 to 55.08. It is in the Health Technology sector (Pharmaceuticals: Major).

Key statistics

Open35.62

Day range35.41 – 37.14

52-week range30.00 – 55.08

Volume5.40 K

Average volume (10 days)3.67 K

Market cap (USD)176.11 B

P/E10.36

EPS (TTM) (USD)3.99

Dividend yield4.40%

Beta (1 year)0.2006

Revenue (TTM) (USD)50.21 B

Employees68.79 K

Performance

+3.18%1 week

+9.69%1 month

−12.21%3 months

−8.33%6 months

−18.04%Year to date

−17.25%1 year

Technical reading

Bullish

Daily summary of what 11 oscillators and 15 moving averages show. See every indicator

Latest headlines

Novo Nordisk set to report Q3 results as investors watch GLP-1 sales and outlookSeeking Alpha · 02 Nov 2026
Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts?Zacks · 02 Nov 2026
Novo Before Q3 Earnings: How Should Investors Play the Stock?Zacks · 02 Nov 2026
Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up NextStocktwits · 02 Nov 2026
Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026

Market data is delayed as each exchange requires (see data coverage). SuperCharting is charting software and gives no investment advice.